# Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients

> **NCT03376672** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Raija Silvennoinen** · enrollment: 120 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03376672
- **Lead sponsor:** Raija Silvennoinen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-04-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03376672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03376672, "Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03376672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*